Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1]. Core Insights - The global new drug business development (BD) remains robust, with approximately 31% of innovative drug candidates introduced by multinational pharmaceutical companies in 2024 coming from China. In the first two months of 2025, there have already been 16 Chinese innovative drug BD projects, expanding from oncology to autoimmune diseases [3]. - The weight loss market is seeing multiple BD agreements, with significant sales figures reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated sales of approximately $27.94 billion in 2024, while Eli Lilly's Mounjaro saw a 124% year-on-year increase in sales to $11.54 billion [5]. - CAR-T cell therapy continues to progress, with global sales expected to reach approximately $4.53 billion in 2024. Chinese companies are also participating in the global CAR-T sales, indicating their technological capabilities [6]. - The gene sequencing industry is accelerating its domestic production capabilities following export restrictions on Illumina's sequencing instruments. Domestic alternatives are rapidly emerging, with several companies receiving regulatory approvals for their sequencing devices [7]. - AI in healthcare is advancing, with various AI models being developed for specific medical fields. Collaborations between tech companies and healthcare providers are enhancing the integration of AI into traditional medical practices [9]. Summary by Sections Industry Trends - The pharmaceutical industry outperformed the CSI 300 index by 0.18 percentage points in the past week, with a weekly increase of 1.77% [23]. - Over the past month, the pharmaceutical sector also outperformed the CSI 300 index by 0.22 percentage points, with a monthly increase of 1.94% [27]. Subsector Performance - The pharmaceutical commercial sector saw the highest weekly increase of 6.44%, while the medical device sector had the lowest at 1.09% [30]. - Over the past year, the chemical pharmaceutical sector had the highest increase of 6.49%, while the biological products sector experienced a decline of 17.62% [37]. Company Recommendations - The report recommends focusing on companies involved in weight loss and NASH, such as Zhongsheng Pharmaceutical, and highlights the potential of companies like Geli Pharmaceutical and Lianbang Pharmaceutical [12]. - Companies engaged in CAR-T technology, such as Kexin Pharmaceutical, are also recommended as they approach market entry [12]. - The report emphasizes the importance of AI integration in medical devices, recommending companies like Anbiping and RunDa Medical for their competitive advantages [12]. Recent Developments - The report notes significant recent financing and regulatory approvals for various companies, indicating a dynamic and evolving market landscape [54][55].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [6]. Core Insights - Roche's innovative therapy TNKase has received FDA approval for the treatment of acute ischemic stroke (AIS), marking it as the first stroke medication approved in nearly 30 years [2][6]. - The pharmaceutical sector showed a performance increase of +0.54% on March 4, 2025, outperforming the CSI 300 index by 0.62 percentage points, ranking 19th among 31 sub-industries [1][6]. - Among sub-industries, in vitro diagnostics (+2.26%), medical devices (+1.17%), and hospitals (+0.85%) performed well, while other bioproducts (-0.06%), medical research outsourcing (+0.07%), and offline pharmacies (+0.17%) lagged [1]. Summary by Sections Market Performance - The pharmaceutical sector's performance on March 4, 2025, was +0.54%, outperforming the CSI 300 index by 0.62 percentage points, with in vitro diagnostics leading at +2.26% [1]. - Notable individual stock performances included BGI Genomics (+20.00%), Shengxiang Biology (+15.24%), and Aidi Pharmaceutical (+11.31%), while Jiangsu Wuzhong (-8.80%), Zhixiang Jintai (-6.22%), and Sihuan Bio (-6.01%) faced declines [1]. Company News - Yinos announced that its clinical immunohistochemistry laboratory received CAP certification, enhancing its clinical testing business prospects [2]. - Tiantan Biological reported that its human coagulation factor IX has completed clinical ethical review and is set to begin Phase III clinical trials, with cumulative R&D investment reaching 25.5766 million yuan [2]. - Sunshine Novo has repurchased 2.716789 million shares, accounting for 2.43% of its total share capital, with a total expenditure of approximately 99.75 million yuan [3]. - Tigermed has repurchased 9.8063 million shares, representing 1.1337% of its total share capital, with a total expenditure of approximately 500.12 million yuan [3].

Buybacks and Shareholding Changes - Guizhou Moutai has repurchased 822,200 shares at a cost of 1.2 billion yuan [1] - SF Holding has repurchased 20,771,400 shares at a cost of 758 million yuan [1] - HeMai Co., Ltd. plans to increase its shareholding by 112 million to 223 million yuan [1] - Chipone Technology's controlling shareholder intends to increase its stake by 50 million to 100 million yuan [1] - Haitai New Light plans to repurchase shares worth 50 million to 100 million yuan [1] - Jiangnan Yifan's directors and shareholders plan to reduce their holdings by no more than 4% [1] - Maxinlin's shareholders plan to reduce their holdings by no more than 2% [1] - Wenke Co., Ltd. has a shareholder intending to reduce its holdings by no more than 1.6% [1] Mergers and Acquisitions - Jiabiou plans to acquire 63.21% of Ouyi Biological for 831 million yuan [1] - Guanghong Technology intends to acquire 100% of AC Company and 0.003% of TIS Company for 733 million yuan [1] - Youyan Silicon is planning a major asset restructuring to acquire 60% of Gaofeng Technology [1] - Chunhui Intelligent Control plans to acquire control of Chunhui Instrument [1] - Aerospace Electric plans to acquire 32.7% of Jiangsu Aolei for 56.933 million yuan [1] Operational Data - Lujiazui reported a net profit growth of 5.26% year-on-year for 2024 [1] - Chang'an Automobile's February sales reached 161,400 units, a year-on-year increase of 5.72% [1] - Ningbo Port completed a container throughput of 3.35 million TEUs in February, up 11% year-on-year [1] - Beibu Gulf Port's February cargo throughput was 23.9793 million tons, a year-on-year increase of 14.56% [1] Contracts and Bids - Hainan Huatie's subsidiary signed a 3.69 billion yuan computing power service agreement [1] - Jiahuan Technology is expected to win a China Mobile procurement project worth approximately 2.185 billion yuan [1] - Gansu Consulting's subsidiary won a bid for the modernization of the Gansu Province Jing Electric Irrigation District [1] - Hongrun Construction's subsidiary jointly won a 248 million yuan user-side energy storage project [1] - Yitong Century is expected to win a 228 million yuan project for China Mobile communication engineering [1] - Zhonglan Environmental Protection is expected to win a 167 million yuan ecological governance project for a landfill [1] - Sinan Navigation signed a major contract worth 145 million yuan [1] - Zhen Shitong won a project for the AV system of the China Merchants Bank headquarters [1] Major Investments - Panjiang Co., Ltd.'s wholly-owned subsidiary plans to invest 6.67 billion yuan in the construction of the Guizhou Energy Puding Power Plant [1] - Jinghua New Materials plans to invest 300 million yuan in the construction of a high-end adhesive material production and R&D center [1] - Sichuan Road and Bridge's subsidiary is participating in the investment of the Panzhihua to Yanyuan Expressway project [1] - Deyue Co., Ltd.'s Malaysian subsidiary signed a land sale agreement worth 194.3 million yuan [1] - Miao Exhibition plans to invest 101 million yuan in a fund [1] - Longtu Photomask plans to increase capital by 100 million yuan to its wholly-owned subsidiary Zhuhai Longtu [1] Other Developments - Berry Gene's AI-related business and products have not yet significantly impacted overall performance [1] - Agricultural Bank appointed Meng Fanjun as vice president [1] - Shanghai Bank's Niu Ren's director qualification has been approved [1] - China Life Insurance's Li Zhuyong resigned from executive director and vice president positions [1] - Fuling Power's chairman Lei Shanchun resigned due to personal work changes [1] - Houl娃 appointed Zhang Mingrui as general manager [1] - Ankai Micro launched a new generation of low-power Bluetooth chip AK1080 series [1] - San Da Membrane's Tiaonan investment project has begun trial operation [1] - Senying Windows triggered conditions to initiate stock price stabilization measures [1] - Aiwei Electronics successfully mass-produced its self-developed 4×80W automotive-grade digital audio amplifier products [1] - ST Haoyuan applied for the cancellation of its stock risk warning [1] - Huasheng Pharmaceutical's first special medical purpose formula food has obtained production license [1] - New Industry's products have received IVDR CE certification [1] - Yinuosi obtained CAP certification in the United States [1] - Changchun High-tech's subsidiary's drug has received approval for additional indications [1] - Fosun Pharma's 24-valent pneumococcal polysaccharide conjugate vaccine clinical trial has been approved [1]

文/梧桐数据中心 2024年全年，科创板共有15家新上市公司。其中，2023年度扣非净利润最高的是艾罗能源（688717），为104029.53万元，最低的为联芸科技（688449），为 3105.03万元；这15家公司的2023年度扣非净利润平均数为24880.15万元，中位数为17444.77万元。 | 序号 | 代码 | 公司简称 | 2022年扣非净利润 | 2023年扣非净利润 | | --- | --- | --- | --- | --- | | 1 | 688717 | 艾罗能源 | 112,051.43 | 104,029.53 | | 2 | 688708 | 佳驰科技 | 45,172.49 | 52,270.68 | | 3 | 688726 | 拉普拉斯 | 10,799.69 | 35,862.01 | | ব | 688615 | 合合信息 | 26,519.24 | 29,742.54 | | 5 | 688709 | 成都华微 | 26.979.51 | 27.667.20 | | 6 | 688692 | 达梦数据 | 25,927.99 | 27,429.53 | | 7 ...

证券代码：688710 证券简称：益诺思 公告编号：2024-023 上海益诺思生物技术股份有限公司 2024 年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 12 月 24 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区郭守敬路 199 号中 心报告厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：关于增加 2024 年度日常关联交易预计额度的议案 审议结果：通过 表决情况： | 1、出席会议的股东和代理人人数 | 117 | | --- | --- | | 普通股股东人数 | 117 | | 2、出席会议的股东所持有的表决权数量 | 53,779,147 | | 普通股股东所持有表决权数量 | 53,779,147 | | 3、出席会议的股东所持有表决权数量 ...

北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN H O N G KONG PARIS MADRID S I L I C O N V A L L E Y 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200041 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52341670 网址/Website:http://www.grandall.com.cn 国浩律师（上海）事务所 关于上海益诺思生物技术股份有限公司 2024 年第四次临时股东大会的 法律意见书 致：上海益诺思生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称" ...

证券代码：688710 证券简称：益诺思 公告编号：2024-021 上海益诺思生物技术股份有限公司 关于增加2024年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海益诺思生物技术股份有限公司（以下简称"公司"或"益诺思"）本 次增加2024年度日常关联交易预计额度事项尚需提交公司股东大会审议； 公司本次增加2024年度日常关联交易预计额度是基于公司正常生产经营 所需，交易合理，定价公允，结算及时，不会对公司及公司财务状况、经营成果 产生不利影响，不会损害公司及全体股东的利益。 一、 本次增加日常关联交易预计额度事项基本情况 （一） 日常关联交易履行的审议程序 2024年11月28日，公司第三届董事会独立董事专门会议2024年第三次会议审 议通过了《关于增加2024年度日常关联交易预计额度的议案》，全体独立董事认 为：公司增加2024年度日常关联交易预计额度，是因公司日常的业务发展需要而 进行，符合公司实际业务需要，定价政策上遵循了公开、公平、公正及自愿原则， 不存在损害 ...

证券代码：688710 证券简称：益诺思 公告编号：2024-016 上海益诺思生物技术股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 127 | | --- | --- | | 普通股股东人数 | 127 | | 2、出席会议的股东所持有的表决权数量 | 101,494,725 | | 普通股股东所持有表决权数量 | 101,494,725 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 71.9924 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 71.9924 | | （%） | | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由董事长魏树源先生主持，会议采用现场投票与网络投票相结 合的表决方式进行表决。本次会议的召集、 ...

证券代码：688710 证券简称：益诺思 上海益诺思生物技术股份有限公司有限公司 2024 年第三次临时股东大会 会议资料 二〇二四年十月 | 2024年第三次临时股东大会须知 1 | | --- | | 2024年第三次临时股东大会会议议程 3 | | 议案一：《关于拟与国药集团财务有限公司签署<金融服务协议>暨关联交易的 | | 议案》 4 | | 议案二：《关于续聘会计师事务所的议案》 5 | 上海益诺思生物技术股份有限公司 2024 年第三次临时股东大会会议资料 2024年第三次临时股东大会须知 根据中国证券监督管理委员会《上市公司股东大会规则》和《公司章程》的 有关规定，为确保公司股东大会顺利召开，特制定大会须知如下，望出席股东大 会的全体人员遵守执行： 一、公司董事会办公室具体负责大会有关程序、资料相关的事宜。 二、股东大会期间，全体出席人员应以维护股东的合法利益、确保大会正常 秩序和议事效率为原则，认真履行法定职责。 三、在大会主持人宣布现场出席会议的股东和股东代理人人数及所持有表决 权的股份总数之前 10 分钟，会议终止登记。未签到登记的股东原则上不能参加 本次股东大会现场会议。 八、股东参加 ...

海通证券股份有限公司关于 上海益诺思生物技术股份有限公司 使用募集资金置换预先投入募投项目 和已支付发行费用自筹资金的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为上海益 诺思生物技术股份有限公司（以下简称"益诺思"或"公司"）首次公开发行股票 并上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等有关规定，对公司使用募集资金置换预先投入募投项目和已支付发行 费用自筹资金的事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海益诺思生物技术股份有 限公司首次公开发行股票注册的批复》（证监许可〔2024〕762 号），公司首次公 开发行人民币普通股（A 股）3,524.4904 万股（以下简称"本次发行"），每股发 行价格为人民币 19.06 元，本次发行募集资金总额 67,176.79 万元，扣除各项发行 费用后，实际募集资金净额为 60,964.49 万 ...